Dafsolimab setaritox

What is dafsolimab setaritox?

Dafsolimab setaritox, also known as grisnilimab setaritox, is an investigational substance with the product name T-Guard. It has no marketing authorisation in the product records, meaning it is not yet approved as a medicine.^[1] The substance is developed by Xenikos BV and has received orphan designation, which is a status given to treatments for rare diseases.^[1] In one product record, dafsolimab setaritox is part of a fixed combination, meaning it is given together with another substance.^[1] The therapeutic area of the trials is diseases of the skin and connective tissue, as well as immune system diseases.^[1]

How does dafsolimab setaritox work?

The available registry data does not describe the mechanism of action of dafsolimab setaritox. The trial record focuses on safety evaluation in patients with early diffuse cutaneous systemic sclerosis, but the precise molecular target or biological pathway is not stated in the provided sources.^[1]

Which conditions is dafsolimab setaritox studied for?

• Diffuse cutaneous systemic sclerosis (dcSSc) — a rare autoimmune disease that causes thickening and hardening of the skin and can affect connective tissue throughout the body. The trial focuses on patients with early dcSSc.^[1]

How is dafsolimab setaritox given?

Dafsolimab setaritox is prepared as a solution for injection or infusion and is given by intravenous infusion, meaning it is delivered directly into a vein over a period of time.^[1]

What do the clinical trials show?

There is one clinical trial of dafsolimab setaritox in the EU Clinical Trials Information System. It is a Phase 1 study, which is the earliest stage of testing in humans, and its status is authorised, meaning it has received approval to proceed.^[1]

The trial includes 13 participants with early diffuse cutaneous systemic sclerosis.^[1] The main outcome being measured is the incidence of Grade 3 or higher adverse events, based on the Common Terminology Criteria for Adverse Events (CTCAE) version 5. This means the study is primarily looking at how safe the treatment is by counting serious side effects that occur from the first infusion until 28 days after the last administration of T-Guard.^[1]

The trial is interventional, meaning participants receive the treatment as part of the study rather than being observed only.^[1] As a Phase 1 study, it is designed to evaluate safety rather than to prove effectiveness.^[1]

What side effects are known?

The trial is specifically measuring the incidence of Grade 3 or higher adverse events, which are serious or severe side effects, during the treatment period and for 28 days after the last infusion.^[1] However, the registry data does not list specific side effects that have been observed. The purpose of the Phase 1 trial is to find out what side effects may occur and how often.^[1]